B
reast carcinoma is the most frequently diagnosed malignancy among women in the Western world and the second leading cause of cancer-related deaths in women (1) . Recent progress in diagnosis and therapy increased the survival of women with estrogen-dependent breast cancer, but estrogen-independent tumors have a poor prognosis, because the treatment options available are not completely satisfactory. New therapeutic approaches must be explored (2) . The involvement of bombesin (BN)͞gastrin-releasing peptide (GRP) and epidermal growth factor (EGF) in breast cancer development and progression suggests that new therapies aimed at interference with these growth factors or their receptors could be developed.
Neuropeptides including BN and GRP act as mitogens or morphogens for some normal and neoplastic tissues including breast (3) and bind to cell surface receptors, which belong to the G protein-coupled receptor superfamily. EGF receptor (EGFR) and human EGFR (HER)-2, -3, and -4, also known as ErbB-2, -3, and -4, are members of the ErbB͞HER type I tyrosine kinase receptor family, which mediates the proliferation and differentiation of normal epithelial cells. An inappropriate overexpression of these receptors as a result of oncogene amplification may contribute to tumor growth and invasion (4) . An overexpression of HER-2, encoded by the neu protooncogene, was found in 25-30% of invasive breast cancers (5) and is associated with chemoresistance and poor prognosis (6) . Because the overexpression of HER-2 is a relatively common phenomenon in breast cancers and its presence is associated with poor survival, HER-2 seems to be an excellent target for therapeutic strategies (5) (6) (7) . A humanized monoclonal antibody against HER-2 was developed and now is in clinical trials in women with metastatic breast cancer and HER-2 overexpression (5) .
In view of the involvement of BN-like peptides in the pathogenesis of a wide range of human tumors, numerous BN͞GRP receptor (GRPR) antagonists have been developed (reviewed in refs. 2 and 8) . BN͞GRP antagonists RC-3095 and RC-3940-II, synthesized in our laboratory (9) , inhibit growth of various experimental tumors including small cell lung carcinoma (SCLC) and breast cancers xenografted into nude mice (2, 8, 10, 11) . Tumor growth inhibition was invariably associated with a significant down-regulation of EGFRs in tumors (11) (12) (13) (14) . In previous studies, we evaluated the effects of BN͞GRP antagonists RC-3095 and RC-3940-II on MDA-MB-231 and MDA-MB-468 estrogen-independent human breast cancers (11, 14) . However, the effects of BN antagonists on HER-2 expression in cancers have not been investigated.
The current preclinical study was carried out on the MDA-MB-435 breast carcinoma cell line, which is derived from a metastatic ductal breast cancer of a 31-year-old female (15) . This tumor line is negative for estrogen and progesterone receptors and expresses all ErbB͞HER receptor family members (16) . The MDA-MB-435 cells were injected orthotopically into the mammary fat pad of nude mice, and the effects of BN antagonists RC-3095 and RC-3940-II on tumor growth were compared. We also evaluated whether these BN antagonists can affect HER-2, -3 and -4 in addition to EGFR. In addition, we investigated the expression of c-jun and c-fos oncogenes after treatment with both BN antagonists. The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Materials and Methods
alanine, Tac is thiazolidine-4-carboxylic acid, and Tpi is 2,3,4,9-tetrahydro-H-pyrido [3,4-b] indol-3-carboxylic acid). The peptides were dissolved in DMSO (final concentration 0.1%) and diluted with 0.15 M sodium chloride in water for injection.
Cell Culture and Animals. The MDA-MB-435 estrogen-independent breast carcinoma cell line was obtained from the American Type Culture Collection. MDA-MB-435 cells were cultured as described (20) . All culture medium components were purchased from GIBCO. Female athymic nude mice (Ncr nu͞nu), 5-6 weeks old on arrival, were obtained from the Frederick Cancer Research Facility of the National Cancer Institute. The mice were housed and fed as described (11) . All animal studies were conducted in accordance with institutional guidelines for the care and use of experimental animals.
Experimental Protocol. The MDA-MB-435 human breast carcinoma cell line was injected orthotopically into the mammary fat pad of nude mice as described previously (21) . The mammary fat pad was exposed under methoxyflurane (Metofane, PittmanMoore, Mundelein, IL) anesthesia and an inoculum of 2 ϫ 10 6 cells per 30 l was injected into the tissue through a 27-gauge needle. The skin incisions were closed with wound clips, which were removed 1 week later. When tumors reached a volume of Ϸ100 mm 3 , the nude mice were divided randomly into three experimental groups of 10 animals each and received the following treatment as s.c. injections: group 1 (control), vehicle solution; group 2, BN͞GRP antagonist RC-3095 at a dose of 20 g͞day per animal; group 3, and BN͞GRP antagonist RC-3940-II at a dose of 10 g͞day per animal. The treatment was continued for 42 days. The tumors were measured once a week with microcalipers, and the tumor volume was calculated as length ϫ width ϫ height ϫ 0.5236. Body weight of the animals was recorded. At the end of the experiment, the mice were anesthetized with methoxyflurane and decapitated. The trunk blood was collected, and the serum was separated and analyzed by RIA. The tumors were dissected, weighed, and snap-frozen for molecular biology analyses. Liver, heart, lungs, kidneys, uterus, and ovaries were removed carefully, cleaned, and weighed.
RNA Extraction and Reverse Transcription (RT)-PCR.
Total RNA was extracted from frozen tissue samples and cells by using RNAzolB (Tel-Test, Friendswood, TX) as described (14) . Three micrograms of total RNA were reverse-transcribed into cDNA by using Moloney murine leukemia virus reverse transcriptase according to manufacturer instructions (Perkin-Elmer). For amplification of cDNA transcripts, gene-specific primers for human GRPR, neuromedin B receptor (NMBR), BN receptor subtype (BRS)-3, EGFR, HER-2, -3 and -4, c-Jun, c-Fos, and ␤-actin were used as described in detail (10, 14, (22) (23) (24) (25) (26) . The number of cycles was determined in preliminary experiments to be within the exponential range of PCR amplification. Negative controls were run in parallel to exclude genomic DNA contamination. PCR products were subjected to electrophoresis on a 2% agarose gel, then stained with ethidium bromide, and visualized under UV light. Bands of PCR products then were scanned and analyzed semiquantitatively by using an imaging densitometer (GS-700, Bio-Rad). All experiments were repeated at least twice, and mRNA levels for each gene were normalized vs. the corresponding levels of mRNA for ␤-actin.
Preparation of Membranes. Tumor tissue was homogenized by using a Polytron in homogenization buffer (50 mM Tris⅐HCl, pH 7.5͞0.25 M sucrose͞0.5 mM EDTA͞0.1 mM phenylmethylsulfonyl fluoride͞5 g/ml leupeptin͞0.5 mg/ml bacitracin). The homogenate was centrifuged at 500 ϫ g for 5 min at 4°C. The supernatant was centrifuged at 45,000 ϫ g for 60 min at 4°C. The final pellet was diluted in washing buffer (homogenization buffer without sucrose) and then frozen at Ϫ70°C until use. Protein concentration was determined with a Bio-Rad protein assay kit using BSA as a standard.
Immunodetection of EGFR and HER-2, -3, and -4. Membrane proteins (20-40 g ) were solubilized in 20 mM Tris⅐HCl buffer (pH 8.0) containing 10% (vol͞vol) glycerol, 1% (wt͞vol) SDS, 1 mM EDTA, and 1 mM DTT and heated for 15 min. Proteins were resolved on a 6% (for EGFR and HER-2, -3, and -4) or 10% (for ␤-actin) SDS͞PAGE and then transferred to nitrocellulose sheets (Hoeffer). The nitrocellulose sheet was soaked in Trisbuffered saline (10 mM Tris⅐HCl, pH 7.5͞50 mM NaCl) containing 0.1% Tween-20 (TBST buffer). Excess protein-binding sites were saturated with TBST buffer containing 5% nonfat dried milk. The blotted membranes were incubated with rabbit polyclonal anti-human EGFR, HER-2, and HER-3 or goat polyclonal anti-human HER-4 and anti-␤-actin antibodies (all from Santa Cruz Biotechnology) diluted 1:2,000-1:3,000 in the TBST buffer for 1 h at room temperature. The immunoreactive proteins were developed with peroxidase-conjugated anti-rabbit and anti-goat IgG antibodies (Santa Cruz Biotechnology) and visualized by a chemiluminescent detection system (Pierce). The bands were analyzed with the imaging densitometer specified above, and the relative protein levels were normalized vs. the corresponding levels of actin.
Histological Methods. Samples of tumor tissue were fixed in 10% buffered formalin. The specimens were embedded in Paraplast (Oxford Labware, St. Louis, MO). Six-micrometer-thick sections were cut and stained with hematoxylin͞eosin. Mitotic and apoptotic cells were counted in 10 standard high-power microscopic fields containing, on the average, 400 cells, and their numbers per 1,000 cells were accepted as the mitotic and apoptotic indices, respectively. For demonstration of the nucleolar organizer region in tumor cell nuclei, the silver nucleolar organizer region method was used (27) . The silver-stained black dots in 50 cells of each tumor were counted, and the silver nucleolar organizer region number per cell was calculated. For the detection of metastases, the entire lungs and three sections of different lobes of the livers were analyzed histologically.
RIAs for Gastrin and EGF. Serum gastrin levels were measured by double-antibody RIA using a kit provided by ICN. EGF was extracted from the mouse sera by a modified acid-ethanol extraction method and measured by RIA as described (11) .
Statistical Methods. Data are expressed as mean Ϯ SE. Statistical analyses of the tumor data were performed by using the Student's t test. All P values are based on two-sided hypothesis testing. Histological data were evaluated by one way ANOVA, and the treated groups were compared with the control by Dunnett's test. P Ͻ 0.05 was considered significant. (Fig. 1) . Therapy with antagonist RC-3940-II resulted in a greater inhibition of tumor burden and volume. After 42 days of treatment with RC-3095, the final tumor volume was decreased by 40% (P Ͻ 0.01), whereas RC-3940-II produced a 65% inhibition (P Ͻ 0.01) compared with controls. At the end of the experiment, there were no significant differences in body weights among the groups. Tumor burden was also reduced significantly by RC-3095 and RC-3940-II to 26.6 Ϯ 1.9 (P Ͻ 0.05) and 24.5 Ϯ 4.9 (P Ͻ 0.05) mg͞g of body weight, respectively, compared with 44.5 Ϯ 5.6 mg͞g of body weight for control. No significant differences in the weights of various organs such as liver, kidney, lung, uterus, ovaries, and heart were observed between the control and treated animals (data not shown).
Results

Effect of BN͞GRP
Serum Gastrin and EGF Levels. Serum gastrin and EGF levels in controls and animals treated with RC-3095 or RC-3940-II were measured. There were no significant changes in serum gastrin levels after chronic treatment with RC-3095 (121.1 Ϯ 13.4 pg͞ml) or RC-3940-II (115.5 Ϯ 10.3 pg͞ml) compared with controls (122.4 Ϯ 6.7 pg͞ml). Serum EGF levels also showed no significant differences after treatment with RC-3095 (3.1 Ϯ 0.4 ng͞ml) or RC-3940-II (2.5 Ϯ 0.2 ng͞ml) compared with those of controls (4.1 Ϯ 0.9 ng͞ml).
Histology. MDA-MD-435 mammary cancers were undifferentiated tumors consisting of polygonal epithelial cells without any special arrangement. The nuclei of cells were round or oval, relatively pale, and contained prominent nucleoli. Scattered giant multinuclear tumor cells were found. The amount of stroma was minimal. The quantitatively measured parameters (the number of mitotic cells, the frequency of apoptosis, or the number of silver nucleolar organizer regions) showed no significant changes after treatment with BN antagonists compared with control values (data not shown). There were no macroscopically detectable metastases in the lungs or livers. Histologically, no metastases were found in the livers, but microscopic metastatic nodules were seen in the lungs of some animals. The occurrence of metastasis and number of metastatic nodules were not significantly different among the groups (data not shown).
Expression of mRNA for BN͞GRPRs in MDA-MB-435 Human Breast
Carcinoma. RT-PCR analyses demonstrated that MDA-MB-435 tumors of control animals expressed mRNA for BRS-1 (GRPR) but not NMBR or BRS-3 ( Fig. 2A) . PC-3 human prostatic, MDA-MB-468 human breast, and H-69 human SCLC cell lines were used as positive controls for GRPR, NMBR, and BRS-3 receptors, respectively (10, 14, 22) .
RT-PCR analyses of mRNA expression for GRPR yielded a product of the expected size of 158 bp for GRPR in samples from the control as well as the RC-3095-and RC-3940-II-treated groups (Fig. 2B) . Amplification with the primers specific for ␤-actin produced a single PCR product of 459 bp (Fig. 2B) . Densitometric analyses of RT-PCR products after normalization of the expression of GRPR mRNA according to the levels of mRNA for ␤-actin revealed that treatment with RC-3095 decreased the expression of mRNA for GRPRs in tumors by 38% (P Ͻ 0.05) and with RC-3940-II by 54% (P Ͻ 0.01) as compared with the controls. To investigate whether the treatment with BN͞GRP antagonists had an effect on the expression of receptors for the ErbB͞HER family, RT-PCR analyses were performed. PCR products of 400, 420, 371, and 142 bp, corresponding to the EGFR and HER-2, -3, and -4, respectively, were detected after ethidium-bromide staining (Fig. 3) . No PCR products were amplified from the negative controls, ruling out the possibility of genomic DNA contamination. Amplification with ␤-actin-specific primers produced a single product of 459 bp from all samples, confirming that there was no degradation of the RNA preparations. Densitometric analyses of the RT-PCR products shown in Table 1 after normalization of the expression of mRNA for HER members family vs. the corresponding ␤-actin mRNA levels demonstrated that RC-3095 diminished mRNA for HER-2 and HER-3 by 30% (P Ͻ 0.05) and 15% (P Ͻ 0.05), respectively. In addition, there was a decrease (not significant) in the expression levels of mRNA for EGFR in the RC-3095-treated group when compared with the control, whereas no effect was observed on the HER-4 mRNA levels ( Table 1 ). The RT-PCR analyses also revealed an even greater decrease in the expression of mRNA for EGFR and HER-2, -3, and -4, amounting to 35% (P Ͻ 0.05), 31% (P Ͻ 0.05), 38% (P Ͻ 0.005), and 28% (P Ͻ 0.005), respectively, in MDA-MB-435 tumors from animals treated with RC-3940-II (Table 1) .
Effect of BN͞GRP Antagonists RC-3095 and RC-3940-II on the Expression of ErbB͞HER Family Receptor Proteins in MDA-MB-435 Human
Breast Cancers. All members of the ErbB͞HER receptor family were investigated by Western blotting with specific antibodies in breast tumors treated with RC-3095 or RC-3940-II. Bands at 170, 185, 160, and 180 kDa correspond to the EGFR and HER-2, -3, and -4 proteins, respectively (Fig. 4) . Densitometric analyses of the bands representing the ErbB͞HER receptor family members after normalization to ␤-actin levels demonstrated that the protein concentration was correlated with the mRNA expression of the same receptor. EGFR and HER-2, -3, and -4 protein levels in MDA-MB-435 cancers from animals treated with RC-3940-II showed a 26% (P Ͻ 0.05), 78% (P Ͻ 0.05), 70% (P Ͻ 0.005), and 28% (P Ͻ 0.05) decrease, respectively (Table 1) . In contrast, RC-3095 reduced only HER-2 protein levels by 41% (P Ͻ 0.005) and HER-3 by 60% (P Ͻ 0.005) and caused a slight and insignificant decrease in EGFR and an increase in HER-4 protein ( Table 1) .
Effect of BN͞GRP Antagonists RC-3095 and RC-3940-II on the Expression of mRNA for c-jun and c-fos Oncogenes in MDA-MB-435 Human
Breast Cancers. In an attempt to elucidate further the mechanism of antitumor action of BN͞GRP antagonists, the expression of c-jun and c-fos oncogenes was investigated by RT-PCR followed by densitometric analyses. Treatment with RC-3095 resulted in a 35% (P Ͻ 0.005) decrease in the mRNA levels for the c-jun oncogene in MDA-MD-435 tumors, whereas RC-3940-II caused a 28% (P Ͻ 0.05) reduction compared with controls ( Fig. 5 A and  B) . A significant decrease in the mRNA levels for the c-fos oncogene was observed also, 14% (P Ͻ 0.005) in the group treated with RC-3095 and 21% (P Ͻ 0.005) in animals receiving RC-3940-II (Fig. 5 A and B) .
Discussion
In accord with our previous findings in MDA-MB-231 and MDA-MB-468 human mammary tumors and MXT mouse mammary cancers (11, 12, 14) , the treatment with our BN͞GRP antagonists RC-3095 and 3940-II results in a marked reduction in growth of MDA-MB-435 human mammary cancers in nude mice. RC-3940-II at doses of 10 g͞day proved to be more powerful than RC-3095 at 20 g͞day. This result could be due to the fact that RC-3940-II shows a higher binding affinity to GRPRs than RC-3095 (19) . Greater responses to RC-3940-II than to RC-3095 have been obtained also in human H-69 SCLCs, OV-1063 ovarian cancers, and MDA-MB-468 and MDA-MB-231 breast cancers (11, 13, 14, 26) .
Various previous studies reported the presence of BN-like peptides in breast carcinomas, and it was demonstrated that they acted as autocrine͞paracrine growth factors in stimulating tumor growth through the BN͞GRPRs (2, 8, 28) . To define the receptors that mediate the effects of the BN͞GRP antagonists, we studied the expression pattern for BN͞GRPRs subtypes in MDA-MB-435 tumors. To date, four structurally distinct recep- Fig. 3 . Expression of mRNA for EGFR and HER-2, -3, and -4 in MDA-MB-435 human estrogen-independent breast cancers grown in nude mice after treatment with RC-3095 (20 g͞day) or RC-3940-II (10 g͞day). Total RNA (3 g) was reverse-transcribed, and cDNA was amplified with specific primers. The PCR products were resolved on a 2% agarose ethidium-bromide gel. mRNA expression for ␤-actin was used as internal control. M, 100-bp molecular DNA marker. The sizes of the expected products are shown. mRNA levels were standardized according to ␤-actin mRNA levels and are expressed as a percentage of control value shown in Table 1 . Results are the mean of at least two independent experiments. Table 1 . The data are the mean of at least three independent experiments.
tors for BN-like peptides have been cloned and characterized: GRPR (GRPR͞BRS-1), NMBR (NMBR͞BRS-2), BRS-3, and BRS-4 (8). Three of the four receptor subtypes (GRPR, NMBR, and BRS-3) are known to exist in mammals, whereas at present, BRS-4 has been identified only in amphibians. GRP and neuromedin B bind to GRPR and NMBR, respectively, with high affinity, whereas BRS-3 responds only to relatively high concentrations of known BN-like peptides, its natural ligand being still unknown. Our study revealed the expression of only BRS-1 (GRPR) in MDA-MB-435 breast cancers. The same GRPR subtype 1 was found by others in malignant breast tissue (3). The inhibition of tumor growth by BN͞GRP antagonists was accompanied by a marked down-regulation of GRPRs as shown by a major fall in the mRNA levels for this receptor. Similar findings in lung cancers and ovarian tumors have been reported (13, 29) . Various investigations demonstrate that GRP and BN regulate cell proliferation through multiple cell-specific signal transduction pathways (30, 31) . Briefly, the signaling cascade includes phospholipase C-␤ (32, 33) , protein kinase C (34), and finally mitogen-activated protein kinase (Elk-1; refs. 35 and 36) , which after phosphorylation is translocated into the nucleus and increases immediate-early expression of oncogenes such as c-fos and c-jun (37, 38) . Both c-fos and c-jun produced by BN may form heterodimers and activate AP-1 sites, stimulating gene expression. In this regard, one of the genes stimulated may be the GRP gene that has a 5Ј-upstream DNA sequence (TGAGTCAG; refs. [39] [40] [41] .
Numerous studies have shown that HER-2 is overexpressed in 25-30% of human breast cancers, and its overexpression identifies patients with estrogen receptor-negative tumors who have a poor prognosis (42) , women with estrogen receptor-positive tumors likely to be resistant to chemotherapy (43) , or those who fail to respond to endocrine therapy on relapse (44) . Recent evidence indicates that by forming heterodimers, HER-2 amplifies the signals generated by other receptors of the ErbB͞ HER family (45) . These receptors are inactive in their monomeric forms and must undergo dimerization to become activated. Heterodimers have a stronger stimulatory action on the growth of normal and tumor cells than the corresponding homodimers (46) , and HER-2͞HER-3 is the most representative heterodimer in breast tumors (47) . Heterodimerization leads to intracellular autophosphorylation at multiple tyrosine residues and provides docking sites for enzymes and adaptor molecules (48) , which transfer the activation signal to the mitogen-activated protein kinases, leading to cell growth and transformation (49, 50) . In addition to the mechanism of a ligand-induced signal generation, a number of reports suggest the possibility of a ligand-independent EGFR and HER-2 transactivation (51, 52). Thus, it has been demonstrated recently that Gq-coupled receptors can phosphorylate EGFRs on tyrosine by a process termed transactivation (53) . In this regard, BN also has been shown to activate the extracellular response kinase pathway, leading to the stimulation of immediate-early genes and proliferation. Considering these findings, it seems that the reduction in mitogenic effects generated through the HER system might be a promising approach to tumor therapy.
Our results show that the treatment of MDA-MB-435 estrogen-independent breast cancers with RC-3940-II significantly decreased the expression of mRNA for all HER family members, whereas RC-3095 reduced only mRNA for HER-2 and HER-3. Accordingly, in addition to decreasing the levels of EGFR, as it was reported in previous studies (11) (12) (13) (14) , BN͞GRP antagonists also induce down-regulation of other members of the ErbB͞ HER family. The expression of mRNA for EGFR and HER-2, -3, and -4 in general was well correlated with receptor protein levels, although Western blot analyses revealed a somewhat greater decrease in HER-2 and HER-3 protein levels after treatment with BN͞GRP antagonists. This shows that BN͞GRP antagonists also may affect the posttransductional regulation of such ErbB͞HER family members.
Previous studies showed that BN͞GRP-like peptides bind to cell surface receptors, which are predominantly coupled to Gq, activate protein kinase C, and stimulate the release of Ca 2ϩ (34) , leading finally to an increase in expression of immediate-early genes such as c-fos and c-jun (38) . Both c-fos and c-jun produced by BN can form heterodimers that regulate the expression of genes with AP-1 activation elements. The gene that encodes for the GRP ligand belongs to this group (40) . Because transcription factors, the nuclear proteins that control DNA transcription and gene expression, are the most distal components of diverse converging mitogenic signal transduction pathways, we evaluated the c-jun and c-fos oncogenes in MDA-MB-435 tumors. Our studies revealed that the levels of mRNA for both oncogenes decreased significantly after treatment with RC-3095 and RC-3940-II. It has been demonstrated that BN-like peptides increase the mRNA levels for these oncogenes in SCLC, glioblastoma, and ovarian cancer, and treatment with different BN͞GRP antagonists blocks c-fos and c-jun gene expression (23, 26, 39) . It was shown also that a mutant form of c-jun, in which the transactivation domain has been deleted, inhibited AP-1 transcriptional activity in different breast cancer cell lines (54) . Consequently, the down-regulation of c-jun and c-fos oncogenes and a possible subsequent AP-1 inactivation may contribute to the antitumor activity of BN͞GRP antagonists.
In conclusion, the present study sheds more light on the inhibitory action of BN͞GRP antagonists RC-3940-II and RC-3095 on the growth of MDA-MB-435 estrogen-independent human mammary cancers. The tumor-inhibitory effect of BN͞ GRP antagonists seems to involve complex mechanisms. After binding, BN͞GRP antagonists down-regulate the subtype-1 BN͞ GRPRs on cancer cells and block the stimulatory effects of autocrine͞paracrine BN-like peptides on tumors. Therefore, a possible transactivation of the ErbB͞HER receptor family members by mitogenic signals is prevented also. Our most important finding is that BN antagonists can produce a reduction in the expression of mRNA and protein levels of all four members of the ErbB͞HER receptor family as well as a decrease in the expression of c-jun and c-fos oncogenes. The mechanisms responsible for these effects need to be clarified fully. Liebow et al. (55) showed that BN-like peptides can up-regulate EGFRs in various cancers, and BN antagonists block this action. Consequently, BN͞GRP antagonists seem to inhibit MDA-MB-435 human estrogen-independent breast carcinoma by blocking the effects of BN-like peptides and inducing a down-regulation of the HER system. BN antagonist RC-3095 is already in clinical phase I͞II trials in patients with EGF-dependent tumors. Herceptin, a monoclonal antibody that targets HER-2, is used presently for the treatment of women with HER-2-overexpressing metastatic breast cancers (56, 57) . Our findings suggest the merit of therapeutic trials with BN antagonists in the management of HER-2-positive breast carcinomas. The use of BN͞GRP antagonists could provide another approach to breast cancer therapy, but further studies are needed to fully elucidate the mechanism of action of these peptide analogs.
